| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
Methylophiopogonanone B targets hypoxia-inducible factor (HIF)-1 alpha, a transcription factor involved in cellular responses to hypoxia. It also targets melanosome transfer pathways in melanocytes and keratinocytes. It increases Rho activity in normal human epidermal melanocytes (NHEMs).
|
|---|---|
| ln Vitro |
In vitro, Methylophiopogonanone B inhibits hypoxia-inducible factor (HIF)-1 alpha activity. It inhibits melanosome transfer to keratinocytes and melanocyte dendrite outgrowth, thereby suppressing pigmentation. It increases Rho activity in normal human epidermal melanocytes (NHEMs).
|
| ln Vivo |
In vivo activity data for Methylophiopogonanone B are limited. Its in vitro inhibition of HIF-1 alpha activity suggests potential applications in conditions where HIF-1 alpha is dysregulated, such as cancer and ischemia. Its anti-pigmentation effects suggest potential applications in skin lightening. Further in vivo studies are needed to confirm its efficacy.
|
| Enzyme Assay |
In vitro assays for Methylophiopogonanone B are conducted to evaluate its HIF-1 alpha inhibitory activity. HIF-1 alpha activity is measured using luciferase reporter assays in cells transfected with hypoxia-responsive element (HRE)-luciferase constructs. Cells are treated with the compound under hypoxic conditions, and luciferase activity is measured. Melanosome transfer assays are performed using co-cultures of melanocytes and keratinocytes.
|
| Cell Assay |
Cellular assays for Methylophiopogonanone B are performed using normal human epidermal melanocytes (NHEMs) and keratinocytes. Cells are treated with compound concentrations ranging from 0.1 to 100 µM for 24-72 hours. Rho activity is measured using pull-down assays. Melanosome transfer is assessed by visualizing melanosome distribution using immunofluorescence. Pigmentation is measured by quantifying melanin content.
|
| Animal Protocol |
In vivo animal studies for Methylophiopogonanone B would typically utilize rodent models of hypoxia-related diseases or pigmentation disorders. The compound is administered orally or topically. Endpoints include HIF-1 alpha activity in tissues, melanin content in skin, and histopathological evaluation.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Methylophiopogonanone B are not well characterized. The compound has a molecular weight of 328.36 and a molecular formula of C₁₉H₂₀O₅. Standard PK studies in rodents would be required.
|
| Toxicity/Toxicokinetics |
Toxicological data for Methylophiopogonanone B are limited. As a natural product-derived compound, it may have a favorable safety profile. No significant acute toxicity has been reported.
|
| References | |
| Additional Infomation |
Reports indicate that methyl ophiopogon B is present in Solomon's seal and Japanese ophiopogon japonicus, and relevant data is available for reference.
Methylophiopogonanone B is a flavonoid from Ophiopogon japonicus that inhibits HIF-1 alpha activity and melanosome transfer. It has a molecular weight of 328.36 and formula C₁₉H₂₀O₅. It is not clinically approved. |
| Molecular Formula |
C19H20O5
|
|---|---|
| Molecular Weight |
328.3591
|
| Exact Mass |
328.131
|
| CAS # |
74805-91-7
|
| PubChem CID |
46886723
|
| Appearance |
White to off-white solid powder
|
| Density |
1.285
|
| Boiling Point |
554.5±49.0 °C at 760 mmHg
|
| Flash Point |
201.5±23.3 °C
|
| Vapour Pressure |
0.0±1.6 mmHg at 25°C
|
| Index of Refraction |
1.617
|
| LogP |
5.22
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
24
|
| Complexity |
445
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
O1C2=C(C([H])([H])[H])C(=C(C([H])([H])[H])C(=C2C([C@@]([H])(C1([H])[H])C([H])([H])C1C([H])=C([H])C(=C([H])C=1[H])OC([H])([H])[H])=O)O[H])O[H]
|
| InChi Key |
UFMAZRUMVFVHLY-CYBMUJFWSA-N
|
| InChi Code |
InChI=1S/C19H20O5/c1-10-16(20)11(2)19-15(17(10)21)18(22)13(9-24-19)8-12-4-6-14(23-3)7-5-12/h4-7,13,20-21H,8-9H2,1-3H3/t13-/m1/s1
|
| Chemical Name |
(3R)-5,7-dihydroxy-3-[(4-methoxyphenyl)methyl]-6,8-dimethyl-2,3-dihydrochromen-4-one
|
| Synonyms |
Methylophiopogonanone B
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~100 mg/mL (~304.6 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.61 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0454 mL | 15.2272 mL | 30.4544 mL | |
| 5 mM | 0.6091 mL | 3.0454 mL | 6.0909 mL | |
| 10 mM | 0.3045 mL | 1.5227 mL | 3.0454 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
